Dr. Reddys Laboratories’ subsidiary -- Promius Pharma has announced that ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US.
ZEMBRACE SymTouch is a prefilled, low-dose, ready to use, 2-step autoinjector containing 3mg of sumatriptan a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief in migraine.
Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.
